Amar Parikh, MD
Interventional Pain Medicine · Albany, NYNPI 1801059118
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Nevro Corp. at 53.4% of the total. Reporting peaked in 2019 at $11,971 and has fallen 91.5% since, to $1,014 in 2025.
Across 267 payments — averaging $104.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$15K
- Boston Scientific$9K
- Prodigy Surgical Distribution, Inc.$1K
- Arthrex$270
- Ferring Pharmaceuticals Inc.$248
- Abbott$247
- plus $2K from 23 others
What the payments were for
- Consulting fees$10,72539%
- Speaking & faculty fees$8,41330%
- Travel & lodging$1,3945%
- Food & beverage$7,26526%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 123 | $14,843 |
| Boston Scientific | 51 | $9,220 |
| Prodigy Surgical Distribution, Inc. | 5 | $1,441 |
| Arthrex | 3 | $270 |
| Ferring Pharmaceuticals Inc. | 13 | $248 |
| Abbott | 7 | $247 |
| AbbVie(2 entities) | 12 | $209 |
| SPR Therapeutics, Inc | 3 | $142 |
| Saluda Medical Americas, Inc. | 2 | $137 |
| Scilex Pharmaceuticals Inc. | 6 | $135 |
| Vertex | 7 | $124 |
| Vertos Medical, Inc. | 3 | $108 |
| Globus Medical | 4 | $95 |
| Relievant Medsystems, Inc. | 2 | $94 |
| Medtronic(2 entities) | 4 | $61 |
| Vertical Pharmaceuticals, LLC | 4 | $60 |
| Pacira Therapeutics, Inc. | 2 | $53 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Sun Pharmaceutical Industries Inc. | 1 | $31 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Axonics, Inc. | 1 | $29 |
| 180 Medical, Inc. | 1 | $28 |
| Foundation Fusion Solutions, LLC | 1 | $28 |
| Bioventus LLC | 1 | $26 |
| Pfizer | 2 | $25 |
| IBSA Pharma Inc. | 1 | $21 |
| Assertio Therapeutics, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza Spinal Cord Stimulation System$9,499
- GENERAL PAIN MANAGEMENT$3,739
- Omnia$3,592
- SPECTRA WAVEWRITER$3,535
- GENERAL - THERAPIES$850
- Superion Indirect Decompression System$137
- Senza$131
- SPRINT PNS System$130
- Evoke$124
How this compares
$27,796 in reported general payments places this provider in the 85th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 18 | $13,211 |
| Fulvestrant | 19 | $10,153 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 299 | $5,032 |
| Pregabalin | 170 | $4,699 |
| Gabapentin | 410 | $3,685 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 143 | $2,875 |
| Duloxetine Hcl | 85 | $2,388 |
| Tramadol Hcl | 349 | $2,184 |
| Oxycodone Hcl | 105 | $1,901 |
| Tizanidine Hcl | 322 | $1,884 |
| Diclofenac Sodium | 123 | $1,444 |
| Celecoxib | 87 | $1,283 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 32 | $1,273 |
| Baclofen | 94 | $1,109 |
| Morphine Sulfate ErMorphine Sulfate | 21 | $902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta | $29 | $13,21118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 132 interventional pain medicine providers in New York.
Other interventional pain medicine in Albany
- Martin FerrilloAlbany$164K
- Edward ApicellaAlbany$13K
- Farrukh AnsariAlbany$6K
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Hemant KaliaRochester$179K
- George ChaseKew Gardens$102K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.